雷米普利对糖尿病肾病患者尿足细胞数量的影响  

Effects of Ramipril on Urinary Podocyte Number in Patients with Diabetic Nephropathy

作　　者：冯秋霞[1] 程丽静[2] 芦露[1] 罗兰[1] 白艳[1] 李萍[1] 季军[1] 高政南[1] 

机构地区：[1]辽宁省大连市中心医院,辽宁大连116011 [2]大连医科大学附属第二医院

出　　处：《中国医学创新》2013年第15期8-10,共3页Medical Innovation of China

摘　　要：目的:应用雷米普利治疗2型糖尿病(T2DM)的肾病患者,比较治疗前、后尿足细胞数量的变化,并探讨雷米普利对肾脏的保护机制。方法:选取56例糖尿病肾病(DN)微量白蛋白尿期的患者,随机分为治疗组和对照组。治疗组每日给予雷米普利5mg,连续服用3个月。应用小鼠抗人肾小球足细胞特异性蛋白(Podocalyxin,PCX)单克隆抗体,采用间接免疫荧光技术检测尿中PCX阳性染色细胞,计数尿足细胞数量。比较治疗前、后两组的尿足细胞数量。结果:雷米普利治疗组的尿足细胞数量较基线明显下降(P<0.05),与对照组相比差异有统计学意义(P<0.05)。结论:雷米普利可以减少DN患者的尿足细胞数量,保护肾功能。Objective： To compare ramipril treatment of type 2 diabetes mellitus （ T2DM ） patients with nephropathy before and after urine enough to the change of the number of cells and to explore ramipril kidney protection mechanisms. Method： 56 patients with diabetic nephropathy （ DN ） microalbuminuria were randomly divided into treatment group and control group. The treatment group was given daily ramipril 5 mg, taking three consecutive months. Applications mouse anti-human monoclonal antibody podocyte-specific protein （ Podocalyxin, PCX ）, positively stained cells using indirect to detect urinary PCX, count the number of urinary podoeytes. To compare the number of urinary podocytes pre-treatment. Result： The number of urinary podocytes ramipril treatment group compared with the baseline decreased significantly （ P〈0.05 ）, compared with the control group, there was a significant difference （ P〈0.05 ） . Conclusion： Ramipril can reduce the number of urinary podocytes DN patients and protect renal function.

关 键 词：糖尿病肾病 足细胞 雷米普利 

分 类 号：R587.2[医药卫生—内分泌]